share_log

Investment Advisory Group LLC Sells 200 Shares of CVS Health Co. (NYSE:CVS)

Investment Advisory Group LLC Sells 200 Shares of CVS Health Co. (NYSE:CVS)

投資諮詢集團有限責任公司出售200股CVS Health Co.(紐約證券交易所代碼:CVS)
Financial News Live ·  2022/09/25 12:11

Investment Advisory Group LLC lowered its position in CVS Health Co. (NYSE:CVS – Get Rating) by 7.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,601 shares of the pharmacy operator's stock after selling 200 shares during the quarter. Investment Advisory Group LLC's holdings in CVS Health were worth $241,000 as of its most recent SEC filing.

據CVS Health Co.(NYSE:CVS-GET Rating)最近向美國證券交易委員會(Securities&Exchange Commission)披露的信息,Investment Consulting Group LLC在第二季度將其在CVS Health Co.的持倉下調了7.1%。該機構投資者在本季度出售了200股後,持有這家藥房運營商的2601股股票。截至最近提交給美國證券交易委員會的文件,投資諮詢集團持有的CVS Health股份價值241,000美元。

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Veriti Management LLC grew its stake in CVS Health by 5.2% in the second quarter. Veriti Management LLC now owns 30,262 shares of the pharmacy operator's stock worth $2,804,000 after purchasing an additional 1,492 shares in the last quarter. Sabal Trust CO boosted its position in CVS Health by 187.9% during the 2nd quarter. Sabal Trust CO now owns 6,244 shares of the pharmacy operator's stock valued at $579,000 after acquiring an additional 4,075 shares in the last quarter. Abacus Planning Group Inc. boosted its position in CVS Health by 5.1% during the 2nd quarter. Abacus Planning Group Inc. now owns 12,566 shares of the pharmacy operator's stock valued at $1,164,000 after acquiring an additional 608 shares in the last quarter. Alhambra Investment Partners LLC boosted its position in CVS Health by 2.9% during the 2nd quarter. Alhambra Investment Partners LLC now owns 15,689 shares of the pharmacy operator's stock valued at $1,454,000 after acquiring an additional 449 shares in the last quarter. Finally, Advisory Alpha LLC boosted its position in CVS Health by 49.9% during the 2nd quarter. Advisory Alpha LLC now owns 3,860 shares of the pharmacy operator's stock valued at $358,000 after acquiring an additional 1,285 shares in the last quarter. Institutional investors own 77.64% of the company's stock.

其他幾家對衝基金和其他機構投資者最近也買賣了該公司的股票。Veriti Management LLC在第二季度增持了CVS Health 5.2%的股份。Veriti Management LLC現在擁有30,262股這家藥房運營商的股票,價值2,804,000美元,上個季度又購買了1,492股。薩巴爾信託公司在第二季度將其在CVS Health的頭寸增加了187.9%。Sabal Trust Co現在擁有這家藥房運營商的6,244股股票,價值579,000美元,此前在上個季度又收購了4,075股。算盤計劃集團在第二季度將其在CVS Health的頭寸增加了5.1%。Abacus規劃集團目前持有這家藥房運營商12,566股股票,價值1,164,000美元,上個季度又購入了608股。Alhambra Investment Partners LLC在第二季度將其在CVS Health的頭寸增加了2.9%。Alhambra Investment Partners LLC現在擁有這家藥房運營商15,689股股票,價值1,454,000美元,上個季度又收購了449股。最後,諮詢阿爾法有限責任公司在第二季度將其在CVS Health的地位提高了49.9%。諮詢公司Alpha LLC現在擁有這家藥房運營商3860股股票,價值35.8萬美元,上個季度又收購了1,285股。機構投資者持有該公司77.64%的股份。

Get
到達
CVS Health
CVS運行狀況
alerts:
警報:

CVS Health Stock Performance

CVS Health股票表現

Shares of CVS stock opened at $98.35 on Friday. The business has a fifty day moving average of $100.20 and a 200 day moving average of $99.22. The firm has a market capitalization of $129.12 billion, a price-to-earnings ratio of 15.99, a price-to-earnings-growth ratio of 1.50 and a beta of 0.73. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.91 and a quick ratio of 0.65. CVS Health Co. has a 1 year low of $81.78 and a 1 year high of $111.25.

CVS股票上週五開盤報98.35美元。該業務的50日移動均線切入位為100.20美元,200日移動均線切入位為99.22美元。該公司市值為1,291.2億美元,市盈率為15.99倍,市盈率為1.5倍,貝塔係數為0.73。該公司的債務權益比為0.67,流動比率為0.91,速動比率為0.65。CVS Health Co.的一年低點為81.78美元,一年高位為111.25美元。

CVS Health (NYSE:CVS – Get Rating) last announced its quarterly earnings results on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.24. The company had revenue of $80.64 billion for the quarter, compared to the consensus estimate of $76.38 billion. CVS Health had a return on equity of 15.19% and a net margin of 2.65%. The firm's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period last year, the firm earned $2.42 EPS. As a group, research analysts expect that CVS Health Co. will post 8.53 earnings per share for the current year.
CVS Health(紐約證券交易所代碼:CVS-GET Rating)最近一次公佈季度收益是在8月3日星期三。這家藥店運營商公佈本季度每股收益為2.40美元,比普遍預期的2.16美元高出0.24美元。該公司本季度營收為806.4億美元,而市場普遍預期為763.8億美元。CVS Health的股本回報率為15.19%,淨利潤率為2.65%。與去年同期相比,該公司本季度的收入增長了11.0%。去年同期,該公司每股收益為2.42美元。研究分析師預計,作為一個整體,CVS Health Co.本年度每股收益將達到8.53美元。

CVS Health Announces Dividend

CVS Health宣佈分紅

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 21st will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.24%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health's dividend payout ratio is currently 35.77%.

該公司最近還宣佈了季度股息,將於11月1日(星期二)支付。10月21日(星期五)登記在冊的股東將獲得每股0.55美元的股息。這意味着年化股息為2.20美元,收益率為2.24%。本次股息除息日期為10月20日(星期四)。CVS Health的股息支付率目前為35.77%。

Insiders Place Their Bets

內部人士下注

In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the sale, the executive vice president now directly owns 109,183 shares of the company's stock, valued at approximately $11,355,032. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Thomas M. Moriarty sold 138,654 shares of the firm's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total transaction of $13,172,130.00. Following the sale, the executive vice president now directly owns 626,273 shares in the company, valued at approximately $59,495,935. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alan Lotvin sold 22,541 shares of CVS Health stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $104.00, for a total value of $2,344,264.00. Following the completion of the sale, the executive vice president now owns 109,183 shares in the company, valued at $11,355,032. The disclosure for this sale can be found here. 0.69% of the stock is owned by insiders.

在CVS Health的其他新聞中,執行副總裁Alan Lotvin在8月4日星期四的交易中出售了22,541股該股。股票以104.00美元的平均價格出售,總成交金額為2344264.00美元。出售後,執行副總裁總裁現在直接持有公司股票109,183股,價值約11,355,032美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站。在其他新聞方面,執行副總裁託馬斯·M·莫里亞蒂在6月28日(星期二)的交易中出售了138,654股公司股票。股票以95.00美元的平均價格出售,總成交金額為13172130.00美元。出售後,執行副總裁總裁現在直接持有該公司626,273股,價值約59,495,935美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過此超鏈接。此外,執行副總裁艾倫·洛文在一筆日期為8月4日星期四的交易中出售了22,541股CVS Health股票。股票以104.00美元的平均價格出售,總價值為2,344,264.00美元。出售完成後,執行副總裁總裁現在擁有該公司109,183股,價值11,355,032美元。關於這次銷售的披露可以找到這裏。該公司0.69%的股份由內部人士持有。

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

Several analysts have issued reports on CVS shares. UBS Group increased their target price on CVS Health from $118.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft increased their target price on CVS Health from $113.00 to $120.00 in a research report on Thursday, August 4th. Loop Capital initiated coverage on CVS Health in a research report on Thursday, June 16th. They set a "buy" rating and a $120.00 target price on the stock. Mizuho increased their price objective on CVS Health from $115.00 to $120.00 and gave the company a "buy" rating in a report on Monday, August 15th. Finally, Evercore ISI increased their price objective on CVS Health from $120.00 to $125.00 and gave the company an "outperform" rating in a report on Wednesday, September 7th. Four research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $117.59.

幾位分析師已經發布了關於CVS股票的報告。瑞銀集團在8月4日週四的一份研究報告中將CVS Health的目標價從118.00美元上調至127.00美元,並給予該公司“買入”評級。德意志銀行Aktiengesellschaft週四在一份研究報告中將CVS Health的目標價從113.00美元上調至120.00美元。Loop Capital在6月16日星期四的一份研究報告中啟動了對CVS Health的報道。他們為該股設定了“買入”評級和120.00美元的目標價。瑞穗將CVS Health的目標價從115.00美元上調至120.00美元,並在8月15日週一的一份報告中給予該公司“買入”評級。最後,Evercore ISI將CVS Health的目標價從120.00美元上調至125.00美元,並在9月7日週三的一份報告中給出了該公司“跑贏大盤”的評級。四位研究分析師對該股的評級為持有,19位分析師給出了買入評級,一位分析師對該公司的股票發出了強烈的買入評級。根據MarketBeat的數據,該公司目前的平均評級為“中等買入”,平均目標價為117.59美元。

CVS Health Company Profile

CVS Health公司簡介

(Get Rating)

(獲取評級)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

CVS Health Corporation在美國提供醫療服務。該公司的醫療福利部門提供傳統的、自願的和以消費者為導向的健康保險產品和相關服務。它為僱主團體、個人、大學生、兼職和小時工、健康計劃、醫療保健提供者、政府單位、政府支持的計劃、勞工團體和外籍人士提供服務。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on CVS Health (CVS)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • 免費獲取StockNews.com關於CVS Health(CVS)的研究報告
  • 華爾街對Datadog的熱情會帶來巨大的收益嗎?
  • MarketBeat:回顧一週9/19-9/23
  • 為什麼特斯拉的股票保持彈性?
  • 小盤股的裁員是樓市的晴雨表嗎?
  • 需要關注的2只半導體類股走勢逆轉

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS – Get Rating).

想看看還有哪些對衝基金持有簡歷嗎?訪問HoldingsChannel.com獲取CVS Health Co.(紐約證券交易所代碼:CVS-GET Rating)的最新13F文件和內幕交易信息。

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受CVS健康日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對CVS Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論